 |
141 Diseases |  |
27 Trials |
|
27 Trials |  |
1501 News |  |
| «1234567891011» |
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Thyrotrophynoma induced hyperthyroidism: what is the best management? () - Oct 1, 2022 - Abstract #ENEA2022ENEA_208;
Therefore, medical management from the beginning is an alternative. Maintenance of euthyroidism depends on the use of medical therapy, such as somatostatin analogs.
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Forty-two patients with thyrotropin-secreting pituitary adenomas: clinical characteristics and therapeutic outcomes () - Oct 1, 2022 - Abstract #ENEA2022ENEA_187;
Test with short-acting octreotide was performed in 24 patients and with long-acting octreotide in 12 patients: 15 and 4 patients, respectively, showed full thyroid hormone normalization...The most effective treatment is neurosurgery. Possible early-postoperative TSH levels model is suggested to predict relapses of TSH-PAs.
- Somavert (pegvisomant) / Pfizer, Sandostatin LAR Depot (octreotide acetate) / Novartis
ACROMEGALY DUE TO A GH-SECRETING PITUITARY ADENOMA IN THE SPHENOID SINUS (Forum 1) - Oct 1, 2022 - Abstract #ENEA2022ENEA_121;
Her medical records included type 2 diabetes mellitus treated with metformin and obesity...Treatment was started with octreotide LAR 20 mg per month...Given the poor control of acromegaly, the dose of octreotide was increased and pegvisomant was added, without normalizing the IGF-1level...The pathology report was compatible with a GH-secreting pituitary adenoma with Ki-67: 1% and p53 negative. After surgery, the IGF-1 level normalized Discussion - It is important to carefully evaluate structures surrounding the sella turcica when a pituitary adenoma is not initially found - Adenomatous pituitary tissue within the sphenoid sinus can be explained by a pituitary tumor that protrudes inferiorly or more rarely, from pituitary embryological remnants located in the sphenoid sinus.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Patterns of somatostatin receptor ligand dosage and titration in patients with acromegaly: a real-world evidence study (Forum 1) - Oct 1, 2022 - Abstract #ENEA2022ENEA_116;
Few patients receiving LAN used EDIs, despite evidence that EDIs with LAN 120 mg provide similar biochemical control to standard dosing intervals for patients whose hormone levels are well-controlled.2,3 These results suggest EDIs may be underused in eligible patients, in whom they might reduce burden of injections and healthcare costs. Bibliography
- octreotide prolonged release (Debio 4126) / Debiopharm, Sandostatin LAR Depot (octreotide acetate) / Novartis
Debio 4126, a new 3-month octreotide formulation, provides sustained release of octreotide, as well as enhanced bioavailability and similar suppression of insulin-like growth factor 1 (IGF-1), compared to monthly Sandostatin LAR in healthy volunteers - interim results (Forum 1) - Oct 1, 2022 - Abstract #ENEA2022ENEA_112;
Bioavailability appeared higher after Debio 4126 administration. Debio 4126 provides sustained release of octreotide over the dosing interval of 12 weeks at a level considered adequate for treatment of patients with acromegaly.
- cabergoline / Generic mfg.
Cabergoline add-on therapy in patients with uncontrolled acromegaly under somatostatin analogues – a multicenter, retrospective, cohort study of non-irradiated patients applying current criteria for disease control (Forum 1) - Oct 1, 2022 - Abstract #ENEA2022ENEA_88;
This response rate was lower compared to previous reports, possibly due to the exclusion of irradiated patients. Only 17% of the patients achieved both optimal GH and IGF-1 levels.
- Sandostatin LAR Depot (octreotide acetate) / Novartis
CHRONIC DIARRHEA IN A PATIENT WITH HIV INFECTION COULD BE DUE TO A CHEST MASS (Convention Center Exhibit Hall: Poster Area) - Sep 28, 2022 - Abstract #CHEST2022CHEST_4523;
Non-AIDS defining malignancies do occur in HIV patients. Clinical acumen should always guide the investigations.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: IVIVC of Octreotide in PLGA-Glucose Microsphere Formulation, Sandostatin® LAR. (Pubmed Central) - Sep 28, 2022
By applying the in vitro release data to the model derived from the IVIVC analysis, pharmacokinetic parameters of SLD could be predicted with the prediction error of ± 10 ~ 15%. IVIVC analysis and pharmacokinetic prediction model of SLD in our study can be an efficient tool for the development of long-acting pharmaceutical dosage forms.
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Hope in ADPKD: Innovation in Therapeutics (Windermere Ballroom X, Hyatt Regency Orlando) - Sep 7, 2022 - Abstract #KIDNEYWEEK2022KIDNEY_WEEK_536;
Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc. Learning Objective(s) Discuss ADPKD risk stratification and selecting patients for therapy Identify emerging and innovative therapies in ADPKD Identify therapies for polycystic liver disease
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. (Pubmed Central) - Aug 26, 2022
In patients with disease control after PRRT, subsequent SSA treatment appeared not to be associated with better PFS or OS. Whether to continue SSA administration upon progression after PRRT requires evaluation in a prospective, randomised, controlled multicentre study with a relatively homogeneous sample.
- | octreotide 3-month extended release (Debio 4126) / Debiopharm
Trial completion date, Trial primary completion date: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Aug 22, 2022
P1b, N=30, Recruiting, Sponsor: Debiopharm International SA
Whether to continue SSA administration upon progression after PRRT requires evaluation in a prospective, randomised, controlled multicentre study with a relatively homogeneous sample. Trial completion date: Jul 2024 --> Feb 2025 | Trial primary completion date: Jun 2024 --> Jan 2025
- ||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Retrospective data, Journal, Adverse events, Real-world evidence: Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study. (Pubmed Central) - Aug 14, 2022
Our findings revealed that octreotide LAR treatment is effective in normalizing GH and IGF-1 levels in Chinese patients with acromegaly. In addition, adverse events related to octreotide LAR use were moderate and well tolerated by the patients.
- | Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
Enrollment change, Trial primary completion date, Metastases: Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) - Aug 12, 2022
P1, N=14, Recruiting, Sponsor: Roswell Park Cancer Institute
In addition, adverse events related to octreotide LAR use were moderate and well tolerated by the patients. N=10 --> 14 | Trial primary completion date: Aug 2022 --> Aug 2023
- | Somavert (pegvisomant) / Pfizer
Trial completion: Acromegaly Combination Treatment Study (clinicaltrials.gov) - Aug 8, 2022
P=N/A, N=76, Completed, Sponsor: Cedars-Sinai Medical Center
N=10 --> 14 | Trial primary completion date: Aug 2022 --> Aug 2023 Recruiting --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Surgery, Metastases: Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery (clinicaltrials.gov) - Aug 4, 2022
P2, N=150, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Completed Active, not recruiting --> Completed
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Signifor LAR (pasireotide long acting release) / Recordati, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. (Pubmed Central) - Aug 2, 2022
Patients with acromegaly and neuroendocrine tumors in Colombia are mainly women and are most frequently treated with lanreotide autogel for acromegaly and with octreotide LAR for neuroendocrine tumors. In addition, a high proportion are managed with maximum doses of long-acting somatostatin analogs.
- | Actinium-225 DOTATATE (RYZ101) / BMS
New P1 trial, Metastases: ACTION-1: Study of RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy (clinicaltrials.gov) - Jul 28, 2022
P1b, N=218, Recruiting, Sponsor: RayzeBio, Inc.
- Sandostatin LAR Depot (octreotide acetate) / Novartis
OCTREOTIDE SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENTS COMPARED TO STANDARD CARE IN PATIENTS WITH ANGIODYSPLASIA-RELATED ANAEMIA: A MULTICENTRE RANDOMISED CONTROLLED TRIAL (Lehar 4) - Jul 20, 2022 - Abstract #UEGW2022UEGW_1274;
P2/3
In addition, a high proportion are managed with maximum doses of long-acting somatostatin analogs. Patients were randomly allocated (1:1) to 40 mg octreotide long-acting release intramuscular every 28 days or standard care... Octreotide treatment effectively reduces the transfusion requirements and endoscopic procedures of patients with GIAD-related anaemia.
- Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Impact of Injection Modalities on Real-World Injection Experience in Patients with Acromegaly or Neuroendocrine Tumors (NETs) Treated With Somatostatin Analog (SSA) Therapy: Data from the PRESTO 2 Survey) () - Jul 16, 2022 - Abstract #ENDO2022ENDO_1704;
Patients considered the most burdensome problems to be local (injection-site) reactions and pain during or after injections. The results of the PRESTO 2 survey showed that LAN had several advantages over OCT, especially in relation to injection-site pain, which highlights the importance of injection route and device on treatment experiences of patients with acromegaly or NETs.
- |||||||| octreotide acetate / Generic mfg.
New P3 trial: A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs (clinicaltrials.gov) - Jul 15, 2022
P3, N=196, Not yet recruiting, Sponsor: Sinotau Pharmaceutical Group
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Prolonged progression-free survival achieved by octreotide LAR plus transarterial embolization in low-to-intermediate grade neuroendocrine tumor liver metastases with high hepatic tumor burden. (Pubmed Central) - Jul 8, 2022
Transarterial embolization plus octreotide LAR can significantly prolong the PFS of neuroendocrine tumor liver metastases, especially with high HTB over 50%. Selected patients with HTB >25% (ki67 ≤10%, absence of bone metastasis, clear tumor margin) could derive prognostic advantage from the combined treatment.
- || octreotide 3-month extended release (Debio 4126) / Debiopharm
Enrollment open: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jul 5, 2022
P1b, N=30, Recruiting, Sponsor: Debiopharm International SA
Selected patients with HTB >25% (ki67 ≤10%, absence of bone metastasis, clear tumor margin) could derive prognostic advantage from the combined treatment. Not yet recruiting --> Recruiting
- ||||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Lanreotide is more expensive & given by deep subQ injection; octreotide long-acting release is given IM. In this comparative study of #NET pt experience w somatostatin analogs, no diff was seen in injection site pain. Read in #JCOOP 👉 https://t.co/RKu08aiwax @DianeReidyLagun (Twitter) - Jun 30, 2022
- |||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical: 3/ I know this sounds bad but I look at patient's butts on CT, esp if on octreotide LAR. Look for injection "granulomas" in gluteal fat. More common that you think... Disclaimer: I have consulted for both Ipsen and Novartis but compensation goes to my institution, not myself. (Twitter) - Jun 22, 2022
- |||| Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical: Some trials look at novel markers/endpoints, others at simple, but relevant questions of great interest to pts. This is such a trial. A RCT looking at pain after octreotide LAR vs. lanreotide. No significant difference. Well done @DianeReidyLagun & Team! https://t.co/J6oWq3TUXp (Twitter) - Jun 22, 2022
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors. (Pubmed Central) - Jun 22, 2022
We found minimal pain with octLAR and lanreotide and no significant pain score differences between the two. Patients indicating a drug preference trended toward favoring octLAR.
- |||| Sandostatin LAR Depot (octreotide acetate) / Novartis
A female in her 60s, severe fatigue, LE edema and refractory ascites. Torrential tricuspid and pulmonary regurgitation. ECOG PS 3. Liver bx c/w grade 1 NET. Very high plasma 5-HIAA (20 x ULN) but no diarrhea. Started on octreotide LAR and referred. CT and DOTA PET at Dx below. (Twitter) - Jun 14, 2022
- | Octreosphere (octreotide extended release) / Xbrane, Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: A prospective study on the efficacy of oral estrogen in female patients with acromegaly. (Pubmed Central) - Jun 9, 2022
In uncontrolled patients with acromegaly, a trial with oral estrogen can be an option for young women. Oral estrogen was well tolerated, but the somatotropinoma that presented ER-α expression was the only somatotropinoma that presented growth during treatment.
- | octreotide 3-month extended release (Debio 4126) / Debiopharm
Trial completion date: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - Jun 3, 2022
P1b, N=30, Not yet recruiting, Sponsor: Debiopharm International SA
Oral estrogen was well tolerated, but the somatotropinoma that presented ER-α expression was the only somatotropinoma that presented growth during treatment. Trial completion date: Dec 2024 --> Jul 2024
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors. (Pubmed Central) - May 31, 2022
Our qualitative data provide valuable insight into the treatment attributes that patients with NETs consider important when making SSA treatment decisions. Factors related to injection administration, side effects, and symptom control are important to patients and should be included in patient-provider communications in clinical contexts.
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
I wonder what the prevalent practice in India/other LMICs post PRRT in nfNET is where you are likely paying out of pocket. No idea how much sandostatin LAR costs there. A monthly long term expense may still pinch your pocket quite a bit.Any insight @Shrikhande_SV @SirohiBhawna (Twitter) - May 9, 2022
- Sandostatin LAR Depot (octreotide acetate) / Novartis
OCTREOTIDE SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENTS COMPARED TO STANDARD CARE IN PATIENTS WITH ANGIODYSPLASIA-RELATED ANEMIA: A MULTICENTER RANDOMIZED CONTROLLED TRIAL (3 - San Diego Convention Center) - May 7, 2022 - Abstract #DDW2022DDW_6838;
Patients were randomly allocated (1:1) to 40 mg octreotide long-acting release intramuscular every 28 days or standard care...Mortality rates did not differ. Conclusion : Octreotide treatment effectively reduces the transfusion requirements and endoscopic procedures of patients with GIAD-related anemia.
- || octreotide 3-month extended release (Debio 4126) / Debiopharm
New P1 trial: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - May 6, 2022
P1b, N=30, Not yet recruiting, Sponsor: Debiopharm International SA
- octreotide chloride FluidCrystal Injection depot (CAM2029) / Novartis
Methodology of the SORENTO clinical trial: Assessing the efficacy and safety of high exposure octreotide subcutaneous depot in patients with GEP-NETs. (Available On Demand; 154b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_2014;
P3
First patient randomized in Nov-2021, with readout (following 194 events) expected by 2024 end. This novel head-to-head superiority trial is anticipated to demonstrate the potential benefits of CAM2029 as a first line-therapy in patients with well-differentiated GEP-NETs.
- ||| Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, P3 data, Journal: Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. (Pubmed Central) - Apr 22, 2022
P3
This novel head-to-head superiority trial is anticipated to demonstrate the potential benefits of CAM2029 as a first line-therapy in patients with well-differentiated GEP-NETs. Oral octreotide was non-inferior to iSRL treatment, and might be a favourable alternative to iSRLs for many patients with acromegaly.
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide (clinicaltrials.gov) - Apr 21, 2022
P4, N=53, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Oral octreotide was non-inferior to iSRL treatment, and might be a favourable alternative to iSRLs for many patients with acromegaly. Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- || Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical data, Observational data, Retrospective data, Journal: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting. (Pubmed Central) - Apr 12, 2022
Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Sep 2023 --> Sep 2024 These real-world data suggest potential clinical and economic advantages of LAN over OCT in the management of patients with NETs in the French population.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method. (Pubmed Central) - Apr 9, 2022
Key formulation steps identified to maximize microsphere yield and minimize residual solvent and initial burst release included (a) addition of acetic acid to the peptide before preparation and (b) annealing the microspheres under vacuum after drying. Controlled release octreotide formulations prepared and investigated in this study could provide a better understanding of the effect of production variables on release performance and supply information useful for making progress in manufacturing of SLAR generic equivalents.
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: Pancreatic neuroendocrine tumor with ectopic adrenocorticotropic hormone syndrome: a case report and 5-year follow-up. (Pubmed Central) - Apr 5, 2022
Although Sandostatin LAR Depot and proton pump inhibitors (PPIs) were used throughout the follow-up period, the tumor relapsed 4 years later...The prognosis of P-NET is poor. Regular long-term follow-up and the application of combined therapies are helpful to control the disease and improve the prognosis.
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Clinical, Journal: A case of enterochromaffin-like cell neuroendocrine tumor associated with parietal cell dysfunction which was successfully treated with somatostatin analogue. (Pubmed Central) - Apr 1, 2022
She was treated with long-acting release octreotide acetate. Complete response was confirmed after 9 months and was maintained for 22 months.
- | sirolimus / Generic mfg.
Journal: Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience. (Pubmed Central) - Apr 1, 2022
Complete response was confirmed after 9 months and was maintained for 22 months. Medical management of CHI is effective, if compliance can be ensured, with good quality of life and neurological outcomes.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Retrospective data, Journal: Clinical parameters and treatment outcome in patients of acromegaly: A retrospective analysis of 51 patients. (Pubmed Central) - Mar 30, 2022
The study shows higher prevalence of Growth Hormone (GH) secreting tumour in younger people and men. Remission rate was highest in patients treated with radiotherapy after partial response to TSS.
- || Sandostatin LAR Depot (octreotide acetate) / Novartis
Review, Journal: Therapeutic advances in ADPKD: the future awaits. (Pubmed Central) - Mar 24, 2022
Thus, in a near future, tailored therapy could be the key to changing the natural history of ADPKD thanks to the vigorous efforts that are being made to implement clinical and preclinical studies in this field. Our review aimed to summarize the spectrum of drugs that are available in the clinical practice and the most promising molecules undergoing clinical, animal, and cultured cell studies.
- || octreotide chloride FluidCrystal Injection depot (CAM2029) / Novartis, Signifor (pasireotide) / Recordati
Clinical, Journal: Combination of pasireotide and octreotide: effects on GH and IGF-I secretion and glucose metabolism in healthy volunteers. (Pubmed Central) - Mar 24, 2022
Our review aimed to summarize the spectrum of drugs that are available in the clinical practice and the most promising molecules undergoing clinical, animal, and cultured cell studies. Combined low doses of pasireotide LAR (5 mg) and octreotide LAR (10-30 mg) provided greater suppression of IGF-I than either single agent and did not increase blood glucose or incidence of AEs versus either agent alone.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Retrospective data, Journal: Effects of Long-Acting Somatostatin Analogues on Lipid Metabolism in Patients with Newly Diagnosed Acromegaly: A Retrospective Study of 120 Cases. (Pubmed Central) - Mar 23, 2022
These patients were treated with either octreotide LAR (OCT) or lanreotide SR (LAN) for 3 months...Fasting insulin, fasting C-peptide, and HOMA-IR were significantly decreased after SSAs treatment. In conclusion, our current study revealed that short-term SSAs treatment improves lipid profiles and other cardiovascular risk factors in patients with acromegaly.
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Comparison of Lanreotide and Octreotide LAR use and outcomes for gastrointestinal neuroendocrine tumors in British Columbia, Canada () - Mar 14, 2022 - Abstract #ENETS2022ENETS_305;
There was no difference in age, sex or site of primary according to type of LA-SSA used, however greater disease control was seen for LAN. This may be partially explained by a later date of reimbursement approval for LAN but warrants further investigation.
- Sandostatin LAR Depot (octreotide acetate) / Novartis
Evaluation of PFS and OS in patients with sporadic, advanced, unresectable, well-differentiated pancreatic neuroendocrine tumors (panNETs) treated initially with Octreotide LAR and methods of further treatment after relapse - Real-world data () - Mar 14, 2022 - Abstract #ENETS2022ENETS_301;
Prolongate of PFS was in NETG1 and in those subjects with BMI>26. In those with DP several others option could be used, which provide OS 98.2 months, compared to PFS only 6.5 months.
- Lutathera (lutetium Lu 177 dotatate) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
Safety and efficacy of peptide receptor radionuclide therapy with 177 Lu-DOTA 0-Tyr 3-octreotate in combination with amino acid solution infusion in Japanese patients with somatostatin receptor-positive, progressive neuroendocrine tumors () - Mar 14, 2022 - Abstract #ENETS2022ENETS_278;
They were treated with 29.6 GBq of 177Lu-DOTATATE (four doses of 7.4 GBq) combined with amino acid solution infusion plus octreotide long-acting release (LAR) 30 mg. PRRT with 177Lu-DOTATATE was well tolerated and showed good outcomes in Japanese patients with unresectable NETs.
- | Sandostatin LAR Depot (octreotide acetate) / Novartis
Trial completion, Trial completion date, Trial primary completion date, Combination therapy: Tolvaptan-Octreotide LAR Combination in ADPKD (clinicaltrials.gov) - Mar 10, 2022
P2, N=20, Completed, Sponsor: Mario Negri Institute for Pharmacological Research
PRRT with 177Lu-DOTATATE was well tolerated and showed good outcomes in Japanese patients with unresectable NETs. Active, not recruiting --> Completed | Trial completion date: Sep 2022 --> Dec 2021 | Trial primary completion date: Sep 2022 --> Dec 2021
- | Somatuline Depot (lanreotide prolonged-release subcutaneous) / Ipsen, Teijin, Sandostatin LAR Depot (octreotide acetate) / Novartis
Journal: Comparing Somatostatin Analogs in the Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. (Pubmed Central) - Mar 9, 2022
Overall, there was no difference in PFS between octreotide LAR and somatuline depot for pts with well-differentiated, metastatic GEP-NETs. A prospective study is worth designing selecting for G.